By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics and BioMerieux are discontinuing their collaboration aimed at identifying biomarkers and developing tests for colon cancer, ExonHit announced today.

The decision reportedly comes on the heels of a recent review of scientific and clinical data from the colon cancer screening research program.

However, the companies plan to continue working together to find biomarkers and develop tests for early-stage prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.